PipelineReview.com16d
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
The existing data underscore its broad potential in both lymphomas and solid tumors. Notably, a ROR1 ADC combined with R-CHP has demonstrated an impressive complete response (CR) rate in a Phase II ...
The EMBO Journal19d
Kick-starting the zygotic genome: licensors, specifiers, and beyond
This month's cover highlights the article Nup358 restricts ER-mitochondria connectivity by modulating mTORC2/Akt/GSK3β signalling by Joseph, Misha Kalarikkal and colleagues. The image shows a human ...
manilatimes1mon
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the treatment of ROR1-positive hematological malignancies and solid tumors. ROR1 is a transmembrane receptor ...
eLife4y
Selective activation of FZD7 promotes mesendodermal differentiation of human pluripotent stem cells
WNT proteins are secreted symmetry breaking signals that interact with cell surface receptors of the FZD family to regulate a multitude of developmental processes. Studying selectivity between WNTs ...
eLife5y
Tailored tetravalent antibodies potently and specifically activate Wnt/Frizzled pathways in cells, organoids and mice
Secreted Wnt proteins regulate development and adult tissue homeostasis by binding and activating cell-surface Frizzled receptors and co-receptors including LRP5/6. The hydrophobicity of Wnt proteins ...